SPORE in Prostate Cancer

这是在西北大学罗伯特·H·鲁里综合癌症中心和芝加哥大学癌症研究中心修改后的前列腺癌孢子续展申请。总体而言，评审员指出，该计划有相当大的优点，在调查人员的专业知识、大量的患者群体和高度支持孢子的环境方面具有优势。我们通过广泛的修订回应了审查委员会提出的意见，从而在整个过程中进一步加强了该计划。主要的变化可以在项目4中找到，在项目4中，我们现在专注于动物研究和临床试验，在项目2中，我们取消了进行动物研究的一个目标。修订后的申请包含四个高度转译的研究项目：(1)前列腺癌间歇性雄激素消融疗法中的5a-还原酶抑制(Wang&Shevrin)，(2)前列腺癌中脂肪生成和瘦素的PEDF调节(Crawford、Gapstur和Lee)，(3)前列腺癌的辐射诱导的肿瘤坏死因子-α疗法(Weichselbaum&Stadler)，以及(4)化学预防制剂Genistein对前列腺癌细胞运动的调节(Bergan&Catalona)。这些项目代表了前列腺癌转化研究的一种平衡方法，包括预防(项目4)、分子流行病学(项目2)、雄激素敏感型晚期癌症的管理(项目1)和局部疾病的治疗(项目3)。孢子组织的领导层强调了拟议的四个核心的高度互动结构，包括行政核心、标本采购核心、生物统计/生物信息学核心以及临床试验和宣传核心。该孢子还拥有灵活而有条理的发展研究和职业发展计划，以鼓励更多的研究人员在前列腺癌研究方面采取主动，并迅速对新的研究机会做出反应。内部和外部咨询委员会评估项目进展，并向孢子首席调查员和联合首席调查员提供指导。我们认为修改后的申请有了显著的改进，我们感谢审查员提出的有益意见。

This is a revised application for renewal of the SPORE in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Cancer Research Center of the University of Chicago. Overall, the reviewers noted that the Program had considerable merit with strengths in the expertise of the investigators, large patient population and an environment highly supportive of the SPORE. We have responded to the comments made by the review committee through extensive revisions and, thus, have further enhanced the program throughout. The major changes can be found in Project 4 where we now focus on animal studies and a clinical trial and in Project 2 where we have eliminated one aim to conduct animal studies. The revised application contains four highly translational research projects: (1) 5a-Reductase Inhibition in Intermittent Androgen Ablation Therapy of Prostate Cancer (Wang & Shevrin), (2) PEDF Regulation of Adipogenesis and Leptin in Prostate Cancer (Crawford, Gapstur and Lee), (3) Radiation-lnducible TNF-alpha Therapy in Prostate Cancer (Weichselbaum & Stadler) and (4) Modulation of Prostate Cancer Cell Motility by the Chemopreventive Agent Genistein (Bergan & Catalona). These projects represent a balanced approach in prostate cancer translational research, including prevention (Project 4), molecular epidemiology (Project 2), management of androgen-sensitive advanced cancer (Project 1), and therapy of local disease (project 3). The leadership of the SPORE emphasizes the highly interactive structures in place for the proposed four cores, that include the Administrative Core, the Specimen Procurement Core, the Biostatistics/Bioinformatics Core, and the Clinical Trials and Advocacy Core. The SPORE also has flexible, yet structured, Developmental Research and Career Development Programs to encourage additional investigators to undertake initiatives in prostate cancer research and to quickly respond to new research opportunities. The Internal and External Advisory Committees evaluate program progress and offer guidance to the SPORE principal investigator and co-principal investigators. We feel that the revised application is significantly improved, and we are grateful to the reviewers for their helpful comments.